Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Overview
Date Founded

1988

Headquarters

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591

Type of Company

Public

Employees (Worldwide)

7,400

Industries

Pharmaceuticals
Biotechnology

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Contact Data
Trying to get in touch with decision makers at Regeneron Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founding Scientist

Founder, President & Chief Executive Officer

Chief Financial Officer & Executive Vice President-Finance

Secretary, Executive Vice President & General Counsel

Executive Vice President & General Manager, Industrial Operations & Product Supply

Senior Vice President & Head-Commercial

Vice President, Head, Regeneron Genetics Center

Vice President & Controller

Executive Vice President, Research

Executive Vice President, Research & Development

Board of Directors

Former President & Chief Executive Officer at Merck & Co., Inc.

Founding Scientist at Regeneron Pharmaceuticals, Inc.

Founder, President & Chief Executive Officer at Regeneron Pharmaceuticals, Inc.

Chairman, Department of Molecular Genetics at The University of Texas - Southwestern Medical Center

Chairman-Molecular Biology Department & Professor at Princeton University

President at Stanford University

Vice Chairman of the Supervisory Board & Secretary at Koninklijke Philips NV

Former Chief Executive Officer at Prudential Financial, Inc.

Former Founder & Director at Peloton Therapeutics, Inc.

Director, Jan & Dan Duncan Neurological Research Institute at Texas Children's Hospital

Paths to Regeneron Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Regeneron Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Harris uses a value investment philosophy in selecting equity and equity-like securities of U.S. and non-U.S. issuers. The firm's investment philosophy spans across large, mid and small cap companies. In addition, Harris may hedge a client's exposure to direct or indirect foreign currencies. In constructing portfolios for their clients, the firm seeks out companies that they believe are trading in the market at significant discounts to their underlying value. Harris believes purchasing businesses at a discount to intrinsic value minimizes risk while providing substantial profit potential. The firm uses a bottom-up approach focused on individual companies, rather than focusing on specific economic factors or industries. Harris generates their research ideas from a variety of internal and external sources. The firm's research process seeks to identify companies selling at a discount to its estimate of intrinsic value.

Details Hidden

In 1951, marking the 25th anniversary of the founding of Loomis, Sayles & Company, Robert H. Loomis sent a clear message to all clients. Click here to read. More than 60 years later, I echo the words of our founder when he said, "we wish to express our gratitude and appreciation to those who, through these difficult years, have helped us to the success we have enjoyed. We look to the future with humility but with confidence." The biggest difference in today's world is that our pace is faster and our playing field is larger. Given this scenario, our job at Loomis Sayles is to keep a laser-like “eye on the ball” particularly during times of uncertainty and volatility, where both risk and opportunity reside. My goal is to ensure that Loomis Sayles remains a broad-based, house of excellence trusted by our clients and recognized for our record of: Attracting and retaining exceptional investment professionals Providing caring, highly ethical and informative services to our clients Producing strong investment performance across our full stable of products The last five years have been a time of tremendous innovation for us. We have grabbed hold of opportunities presented by market upheaval to unearth some tremendous investments, build off our base and empower people to construct and test new capabilities. By integrating these with existing capabilities, (quantitative research, deeper risk analysis, greater macro-economic firepower, absolute return-oriented strategies and securitized capabilities), I believe we are a better investment firm than ever. On behalf of all Loomis Sayles employees, thank you for placing your confidence in us. From my personal vantage point, I am more confident than ever about the future of our company and the skills and passion of our people to deliver excellence in their work. We look forward to serving your investment needs as we face the ever-changing future together.

Details Hidden

Polen Capital employs a disciplined, bottom-up, concentrated US, Global and International equity investment strategies that focus on high quality growth investments. The Polen Focus Growth strategy invests in a concentrated portfolio of primarily large-cap US common stocks with sustainable competitive advantages. The Polen Global Growth strategy invests in a concentrated portfolio of outstanding US and international businesses with competitive advantages and the potential for sustained superior growth. It emphasizes sustainable earnings growth and focuses on companies with high returns on capital and double digit earnings growth. The Polen International Growth strategy applies the same philosophy as the Focus Growth and Global Growth portfolios, but invests exclusively in businesses domiciled outside of the US.

Recent Transactions
Details Hidden

Regeneron Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Regeneron Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Regeneron Pharmaceuticals, Inc. issued Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Auditor

Advised onRegeneron Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onRegeneron Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onRegeneron Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onRegeneron Pharmaceuticals, Inc. issued Common Stock

Advisors & Consultants
Advisor

Dean, Translational Biomedical Sciences at Icahn School of Medicine at Mount Sinai

Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP

Advisor

Former Senior Vice President, Administration & Assistant Secretary at Regeneron Pharmaceuticals, Inc.

Clients

Cigna is more than a health insurance company. They are a global health service company. Cigna works with employers and organizations around the world helping employees stay healthy and on the job. They work closely with brokers and consultants to develop innovative programs, help individuals and families improve their health, well-being and sense of security—and lower their medical costs. And, Cigna provides access to a global network of local physicians and hospitals—as well as 24/7/365 live customer service.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

Key Stats and Financials As of 2018
Market Capitalization
$33.5B
Total Enterprise Value
$40.8B
Earnings Per Share
$21.29
Revenue
$6.71B
Enterprise Value Sales
6.08x
TEVNet Income
16.68x
Debt TEV
0.02x
Net Profit
$2.44B
Total Equity
$8.76B
Total Debt
$708M
EBITDAMargin
39.97%
Enterprise Value EBITDAOperating
15.2x
EBITDA
$2.68B
Three Year Compounded Annual Growth Rate Of Revenue
17.81%
Five Year Compounded Annual Growth Rate Of Revenue
26.1%
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
$475K
2010
Investments
Details Hidden

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The firm primarily focuses on hearing disorders, including noise-induced hearing loss; residual hearing preservation or improved sound fidelity with cochlear implants; presbycusis or age-related hearing loss; tinnitus, a persistent ringing in the ears; and genetic hearing loss. It also offers drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded by Kevin Paul Starr, M. Charles Liberman, Gabriel Corfas, Ulrich Müller and Albert Edge in October 2015 and is headquartered in Boston, MA.

Details Hidden

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Suppliers
Intellia Therapeutics, Inc. Medical Support Services | Cambridge, MA

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Adverum Biotechnologies, Inc. Pharmaceuticals | MENLO PARK , CA

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Adicet Bio, Inc. Holding Companies | Beverly Hills, CA

Adicet Bio, Inc. operates as a biopharmaceutical company focused on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits and is headquartered in Beverly Hills, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Awards & Honors
Rank #85
2017
Fortune Magazine - The 100 Best Companies to Work For
Sponsored by Fortune Magazine
Rank #583
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #5
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Regeneron Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Regeneron Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Regeneron Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/regeneron-pharmaceuticals-inc-13601
  • https://relationshipscience.com/organization/regeneron-pharmaceuticals-inc-13601